Skip to main content
Premium Trial:

Request an Annual Quote

OGT Licenses Tridend Tech to UK Biotech MassTag

NEW YORK (GenomeWeb News) — Oxford Gene Technology today said it has granted UK biotech MassTag Technologies licensing rights to its Tridend technology.
 
The company said the option on the license will become exclusive when MassTag completes a fund-raising campaign. Also through the agreement, OGT will become a minority shareholder in MassTag.
 
The technology was developed under former OGT subsidiary Tridend and is suited for mass spec systems because it offers multiplexing and ability to analyze multiple samples, according to OGT.
 
OGT CEO Mike Evans said the agreement came after a strategic review, when OGT began focusing on finding partnerships in the microarray field.
 
Financial terms of the agreement were not disclosed.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.